Eisai and Nuvation Bio report taletrectinib MAA validated by European regulator

Iterion Therapeutics reports first patient dosed in phase 1/2 trial of tegavivint in colorectal cancer

SciTech Development reports early-stage clinical data from Phase 1a trial of ST-001 nanoFenretinide at USCLC Annual Workshop 2026

Clarity Pharmaceuticals signs copper-64 manufacturing agreement with Theragenics

Merck to acquire Terns Pharmaceuticals for USD6.7bn

Myosin Therapeutics granted USD2m funding from Florida Department of Health

Akeso's Phase II trials of AK146D1 and AK138D1 approved in China

Abbott completes Exact Sciences acquisition

GE HealthCare's Photonova Spectra gains FDA clearance

HUTCHMED launches Phase III trial of HMPL-760 for DLBCL in China

GSK secures Japan Orphan Drug status for lung cancer ADC

TheraCryf advances lead addiction programme to final preclinical stage

Dizal meets primary endpoint in Phase 3 study of ZEGFROVY (sunvozertinib) monotherapy

Novartis to acquire PI3K-alpha inhibitor program from Synnovation in deal worth up to USD3bn

IBA and Telix partner to expand US radiopharmaceutical manufacturing capacity